Richard Keith Levin

US Patent:

57245800, Mar 3, 1998

Filed:

Mar 20, 1997

Appl. No.:

8/822177

Inventors:

Richard I. Levin - New York NY
Michael W. Cox - Point Pleasant NJ

Assignee:

qmed, Inc. - Lawrence Harbor NJ

International Classification:

G06F 1730

US Classification:

395615

Abstract:

A system and method of automatically formulating an alpha-numeric comprehensive management and prognosis report at a centralized data management center for a patient at a remote location is defined comprising: means for converting information regarding the condition of the patient into data; a first telecommunications means for transferring data to the centralized data management center; and processing means at the centralized data management center for receiving the data and for generating the comprehensive management and prognosis report based on analysis of the data. A storage means is also provided at the centralized data management center for maintaining a record of the data received by and transmitted from the centralized data management center in a relational data base format.

US Patent:

59325585, Aug 3, 1999

Filed:

Sep 13, 1996

Appl. No.:

8/712942

Inventors:

Bruce N. Cronstein - New York NY
Richard I. Levin - New York NY

Assignee:

New York University - New York NY

International Classification:

A61K 3170

US Classification:

514 46

Abstract:

Agonists of the adenosine A. sub. 2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A. sub. 2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclopropyladenosine, 5'N-methyl-carboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.

US Patent:

60203218, Feb 1, 2000

Filed:

Feb 3, 1999

Appl. No.:

9/243538

Inventors:

Bruce N. Cronstein - New York NY
Richard I. Levin - New York NY

Assignee:

New York University - New York NY

International Classification:

A61K 3170
C07H 19167

US Classification:

514 46

Abstract:

Agonists of the adenosine A. sub. 2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A. sub. 2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclo-propyladenosine, 5'N-methylcarboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.